Van der Vaart Sandra D., the EVP and Chief Legal Officer of Labcorp (LH), has filed 40 Form 4 transactions across the single company, with a pronounced disposition bias. Her total open-market sales reached roughly $3.5 million, while she recorded zero open-market purchases, indicating a consistent pattern of selling rather than accumulating shares. The most recent six filings, spanning February and March 2026, reinforce this trend: she executed two open-market sales on February 27, 2026, each valued at $155,999.54, alongside several automatic "F" transactions where shares were withheld to cover tax obligations, including a $730,530.36 withholding on March 26, 2026.
The selling activity has been steady but not uniform, with notable spikes in value. The largest single sale occurred on August 13, 2025, when she disposed of shares worth $1,059,371.38, following an option exercise valued at $512,971.29 on the same date. Earlier, on May 1, 2025, she sold $452,884 in LH stock, and on February 25, 2025, she sold $330,208.20. A smaller sale of $42,167 on May 14, 2024, rounds out the historical record. Interspersed with these sales are routine "A" grants (compensation awards with no cash value) and "M" option exercises, which are mechanical in nature and do not reflect discretionary buying.
The pattern is clear: van der Vaart has been a net seller of Labcorp shares over the past two years, with no open-market purchases to counterbalance the outflow. Her sales are clustered around option exercises and vesting events, typical of an executive monetizing equity compensation, but the absence of any "P" transactions suggests she has not been
AI-assisted summary